Related Experiment Video
Updated: Jun 19, 2026
09:11
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
Cell-based therapy for ischemic heart disease: a clinical update
Jeremy L Herrmann1, Aaron M Abarbanell, Brent R Weil
1Clarian Cardiovascular Surgery, Indianapolis, Indiana, USA.
The Annals of Thoracic Surgery
|October 27, 2009
Summary
Progenitor cell therapy shows promise for ischemic heart disease, with early trials indicating modest functional improvements. Further research is needed to understand cell mechanisms and optimize long-term benefits for myocardial regeneration.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Cell Therapy
Background:
- Ischemic heart disease remains a leading cause of mortality worldwide.
- Progenitor cell therapy offers a potential regenerative approach for myocardial repair.
- Current understanding of progenitor cell mechanisms and long-term efficacy in ischemic conditions requires further elucidation.
Purpose of the Study:
- To review current knowledge on progenitor and stem cells for myocardial regenerative therapy.
- To discuss various cell delivery routes for ischemic myocardium.
- To summarize clinical trials of bone marrow-derived progenitor cell therapy and explore future directions.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of mechanisms of action for progenitor and stem cells in cardiac repair.
- Synthesis of data from clinical trials investigating bone marrow-derived progenitor cells.
Main Results:
- Early clinical trials demonstrate modest functional improvements following autologous bone marrow-derived progenitor cell therapy.
- The duration of therapeutic benefits from progenitor cell delivery remains uncertain.
- Ongoing research focuses on enhancing progenitor cell survival and cardioprotective functions.
Conclusions:
- Progenitor cell therapy holds significant potential for treating ischemic heart disease.
- Optimizing cell survival, delivery, and understanding underlying mechanisms are crucial for clinical success.
- Future research should focus on improving the long-term efficacy and regenerative capacity of these therapies.
More Related Videos
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...